Now I have all the information needed. Let me synthesize the final review.

## Summary

ProteinVista introduces a full-atom 3D CNN that voxelizes protein structures at 1.0Å resolution across five heavy-atom channels, uses adaptive boxing to minimize empty space, and is pre-trained on ~500K AlphaFold2 structures. Despite using 123M parameters (vs. ESM-2's 650M) and ~1% of the GPU-hours for pre-training, it matches or outperforms ESM-2 on transporter-substrate classification, enzyme-substrate classification, and drug-target IC50 regression. A simple ensemble with ESM-2 further improves the classification tasks, demonstrating complementarity between sequence and structure signals.

## Strengths

1. **Clear compute-efficiency demonstration with concrete numbers.** ProteinVista (123M params, ~500K pretraining structures, 48 hrs on 4 A100s) outperforms ESM-2_650M (650M params, ~250M sequences, 7 days on 128 H100s) on all three binding benchmarks while using ~1% of the GPU-hours for pretraining. Inference is also substantially faster: 20 seconds vs. 426 seconds per 1000 proteins on an A100 (Section 4.3, Figure 3). These are specific, well-documented comparisons.

2. **IC50 regression shows a decisive advantage for structure-based encoding.** ProteinVista achieves R²=0.69 vs. ESM-2_650M's 0.61 on BindingDB, with p < 10^{-304} on a one-sided Wilcoxon signed-rank test (Section 3.2, Table 2). The ensemble with ESM-2 does not improve (R²=0.68), indicating the structure encoder captures signal the sequence model cannot reach. This is the paper's strongest single piece of evidence.

3. **Statistical tests validate complementarity on classification tasks.** The ESM-ProteinVista ensemble outperforms either single model on TSP and ESP across all metrics (Table 1), with McNemar's test showing significantly lower error rates (p < 10^{-13} for TSP, p < 10^{-17} for ESP). Stratified analysis by sequence identity, TM-score, and pLDDT (Figure 2a-c) shows that sequence and structure contribute in different regimes.

4. **Systematic ablation studies.** Section 4.2 and Figure 2e quantify the impact of pretraining objective (contrastive vs. Rosetta regression, 1.0% R² difference), voxel resolution (1.5Å vs 1.0Å, 1.1% drop), and inference-time augmentation (single vs. five views, 6.4% drop). This allows practitioners to understand which design choices matter most.

5. **Honest reporting of negative results.** The GO annotation experiment (Section 3.4) shows ProteinVista underperforms ESM-2 (F_max 0.57 vs. 0.62), consistent with the paper's framing that structure helps most on tasks requiring fine-grained geometry. This transparency strengthens the overall contribution.

## Weaknesses

### Fatal
None.

### Major

1. **The optimized pipeline (OP) comparison is asymmetric.** In Section 3.3, the ESM-ProteinVista_OP model (with joint fine-tuning of MolFormer, additional contrastive training, and prediction averaging) is compared against published SOTA methods (SPOT, ProSmith-ESP, Fusion_ESP). But ESM-2 itself is *not* evaluated under the same optimized pipeline. It is therefore impossible to determine whether the improvement over SOTA comes from ProteinVista's structure encoder or from the pipeline optimizations. If a similarly optimized ESM-2 pipeline would match or exceed SOTA, the contribution of ProteinVista *per se* is not demonstrated. The authors should run ESM-2_650M through the same OP pipeline.

### Minor

2. **No variance or uncertainty estimates across runs.** All results appear to come from single runs. Without standard deviations across multiple random seeds (3–5 replicates), the reader cannot assess whether observed differences (e.g., the +1.5% accuracy gap on TSP between ProteinVista and ESM-2_650M) are statistically robust to model retraining variability. The statistical tests (McNemar's, Wilcoxon) measure paired prediction differences but not retraining variability.

3. **Primary pretraining distills ESM-2 knowledge, but the paper is adequately transparent about this.** The contrastive objective pulls ProteinVista embeddings toward ESM-2 embeddings (Section 2.3). The title's "outperforms" framing could mislead a casual reader. However, the Rosetta-only ablation (Section 4.2) shows that even without ESM-2 distillation, ProteinVista achieves R²≈0.68 on IC50 vs. ESM-2's 0.61, so the core claim is not circular — it is weakened in framing but not invalidated. The paper would be stronger by featuring the Rosetta-only result more prominently in the main comparison.

4. **The IC50 ensemble degradation (R² 0.69 → 0.68) is not analyzed in depth.** The paper's explanation — that "accurate affinity prediction relies strongly on fine-grained structural detail" — is plausible but not supported by error correlation analysis or alternative fusion methods. This does not undermine the main results, but the complementarity narrative would benefit from understanding why naive averaging hurts on this task.

### Trivial

5. **Batch size for the contrastive InfoNCE loss is not reported.** This is needed for reproducibility.

6. **Some presentation issues with Figure 2:** Circle areas in panels (a)-(c) are proportional to data point count, making visual comparison of MCC across bins with small circles difficult.

## Nice-to-Haves

- **Structure-aware GNN baselines.** The paper currently compares only against sequence models (ESM-2, SPOT, ProSmith-ESP, Fusion_ESP). Adding a 3D GNN baseline such as GVP or SchNet would clarify whether the 3D CNN architecture itself drives the gains or whether any atom-level structure representation works.
- **pLDDT distribution for the main test sets** (Tables 1 and 2). Figure 2d shows the distribution for TSP, but similar reporting for ESP and BindingDB would help assess how much overall results depend on structure quality.
- **Analysis of why the ensemble works for TSP/ESP but not IC50**, e.g., per-sample error correlation or a learned fusion approach instead of naive averaging.

## Removed Points

- **"ESM-2 inference time seems unusually high"** — The paper reports 426s for 1000 proteins on A100 (~0.43s/protein). This is within the expected range for a 650M-parameter transformer; the criticism was speculative and not supported by concrete evidence from the paper.
- **"ESM-2 models are used in a frozen embedding setting"** — The paper states models were "fine-tuned under identical conditions" (Section 3.1). The critic misread "fixed MolFormer embeddings" as applying to ESM-2, when the paper clearly refers to MolFormer being fixed, not ESM-2.
- **"Missing comparison against strong atom-level graph baseline"** — Moved to Nice-to-Have; the paper explicitly scopes its comparison to sequence transformers and SOTA substrate methods, which is a reasonable scope.
- **"Missing related works"** — Not included per review guidelines (cannot verify).

## Novel Insights

None beyond the paper's own contributions. The reviews did not surface any perspective on the paper that the paper itself does not articulate.

## Suggestions

1. Run ESM-2_650M through the same optimized pipeline (joint MolFormer fine-tuning, contrastive network, ensemble averaging) and report the result alongside ESM-ProteinVista_OP. This is the single most important addition for the revision.
2. Report means and standard deviations over 3–5 random seeds for all main experimental tables.
3. Feature the Rosetta-only ablation result (R²≈0.68 vs. ESM-2's 0.61) in the main comparison table, and reframe the contrastive pretraining variant as an additional improvement rather than the primary result.
4. Add a brief error correlation analysis or alternative fusion experiment for the IC50 ensemble to explain why the ensemble does not improve.
5. Report the batch size used for the InfoNCE contrastive loss.

## Score and Decision

**Calibration summary:**

| Anchor | Score | Round | Comparison |
|--------|-------|-------|------------|
| PPBind (xNDydjYBmC) | 4.60 (Reject) | 1 | Weaker — lacks SOTA baselines entirely, has duplicate figure issue |
| EquiPocket (umUIYdLtvh) | 5.50 (Reject) | 1 | Comparable scope but ProteinVista has stronger, more diverse experimental validation |
| BindNet (AXbN2qMNiW) | 5.67 (Accept) | 1,2 | Similar quality — both have pretraining + fine-tuning pipelines; BindNet had data leakage concerns, ProteinVista has OP asymmetry |
| Pre-training SS&S (BEH4mGo7zP) | 5.75 (Accept) | 2 | Similar structure-aware pretraining; ProteinVista shows clearer compute advantage and stronger IC50 results |
| CheapNet (A1HhtITVEi) | 6.00 (Accept) | 1 | Comparable — CheapNet has tighter evaluation on affinity prediction; ProteinVista has broader task coverage |
| 3DMolFormer (RgE1qiO2ek) | 6.25 (Accept) | 2 | Slightly stronger — more novel unified framework for docking and design |
| AtomSurf (ARQIJXFcTH) | 6.75 (Accept) | 2 | Slightly stronger — more comprehensive benchmarking across representations |
| GroupBind (zDC3iCBxJb) | 6.75 (Accept) | 2 | Stronger — sets new SOTA with novel group-docking paradigm |

**Round 1 bracket:** 4.5 – 7.5 (above rejected papers with fatal flaws, below very strong top-tier papers around 8.0).

**Round 2 narrowing:** ProteinVista is clearly stronger than PPBind (4.6) and EquiPocket (5.5). It is comparable to BindNet (5.67), Pre-training SS&S (5.75), and CheapNet (6.0), but has one notable gap the others do not (asymmetric OP comparison). It falls below AtomSurf (6.75) and GroupBind (6.75) in terms of evaluation comprehensiveness and novelty, respectively.

**Final score:** 6.0. The paper makes a genuine contribution — demonstrating that full-atom 3D CNNs are tractable at scale and provide meaningful complementary signal to sequence models — but the asymmetric OP pipeline comparison, lack of variance estimates, and minor framing issues prevent it from being a top-tier paper. With revisions (particularly adding the ESM-2 baseline under the OP pipeline and variance estimates), this would be a solid accept.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>